Drug Interactions between chikungunya vaccine, recombinant (cvx 329) and sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 308)

Consumer information for this interaction is not currently available.

MONITOR: The safety, immunogenicity, and efficacy of SARS-CoV-2 (COVID-19) vaccines when administered concurrently with other vaccines have not been extensively studied. Experience with non-COVID-19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously compared to when they are given alone. A study of inactivated influenza vaccines coadministered with the AstraZeneca or Pfizer BioNTech COVID-19 vaccine reported acceptable immunogenicity and reactogenicity, without any additional safety concerns. In a separate study, coadministration of the Novavax COVID-19 vaccine with inactivated influenza vaccine did reveal some attenuation of the antibody response to COVID-19 but was still associated with high efficacy against COVID-19. Additionally, the results of a study examining the administration of a Moderna COVID-19 booster vaccine given concomitantly with recombinant zoster vaccine versus separated by 2 weeks revealed immunological noninferiority and a similar safety and reactogenicity profile in adults 50 years of age and older. Clinical data are not available for all the possible vaccine combinations; however, available data suggest that COVID-19 vaccines may be coadministered with most other vaccines when necessary.

MANAGEMENT: The U.S. Centers for Disease Control and Prevention (CDC) advises that COVID-19 vaccines and other vaccines may now be administered without regard to timing, including simultaneous administration on the same day as well as coadministration within 14 days. COVID-19 vaccines should not be mixed with any other vaccine in the same syringe or vial. If multiple vaccines are administered during a single visit, each injection should be administered at a different injection site. For adolescents and adults, the deltoid muscle can be used for more than one intramuscular injection, but each injection should be separated by 1 inch or more if possible. It is also advisable to administer COVID-19 vaccines and vaccines that may be more likely to cause a local reaction (e.g., tetanus toxoid-containing and adjuvanted vaccines) in different limbs whenever possible. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for more specific recommendations.